Opus Genetics Valuation
| IRD Stock | 2.12 0.11 5.47% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Opus Genetics holds a recent Real Value of USD3.39 per share. The prevailing price of the company is USD2.12. Our model determines the value of Opus Genetics from analyzing the company fundamentals such as Current Valuation of 108.87 M, shares owned by insiders of 14.17 %, and Return On Equity of -3.39 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Opus Genetics' valuation include:
Price Book 23.2308 | Enterprise Value | Enterprise Value Ebitda (2.55) | Price Sales 9.473 | Enterprise Value Revenue 7.4401 |
Undervalued
Today
Please note that Opus Genetics' price fluctuation is unstable at this time. Calculation of the real value of Opus Genetics is based on 3 months time horizon. Increasing Opus Genetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Opus stock is determined by what a typical buyer is willing to pay for full or partial control of Opus Genetics. Since Opus Genetics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Opus Stock. However, Opus Genetics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.12 | Real 3.39 | Target 7.8 | Hype 2.02 | Naive 1.86 |
The real value of Opus Stock, also known as its intrinsic value, is the underlying worth of Opus Genetics Company, which is reflected in its stock price. It is based on Opus Genetics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Opus Genetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Opus Genetics helps investors to forecast how Opus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Opus Genetics more accurately as focusing exclusively on Opus Genetics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Opus Genetics' intrinsic value based on its ongoing forecasts of Opus Genetics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Opus Genetics' closest peers. If more than one evaluation category is relevant for Opus Genetics we suggest using both methods to arrive at a better estimate.
Opus Genetics Cash |
|
Opus Genetics Total Value Analysis
Opus Genetics is currently projected to have company total value of 108.87 M with market capitalization of 138.62 M, debt of 18.84 M, and cash on hands of . Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Opus Genetics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
108.87 M | 138.62 M | 18.84 M |
Opus Genetics Investor Information
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.86. Opus Genetics last dividend was issued on the 6th of November 2020. The entity had 1:4 split on the 6th of November 2020. Based on the key indicators related to Opus Genetics' liquidity, profitability, solvency, and operating efficiency, Opus Genetics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Opus Genetics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Opus Genetics has an asset utilization ratio of 29.82 percent. This indicates that the Company is making USD0.3 for each dollar of assets. An increasing asset utilization means that Opus Genetics is more efficient with each dollar of assets it utilizes for everyday operations.Opus Genetics Ownership Allocation
Opus Genetics owns a total of 68.96 Million outstanding shares. Opus Genetics holds significant amount of outstanding shares owned by insiders and institutional investors . Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Opus Genetics Profitability Analysis
The company reported the last year's revenue of 10.99 M. Reported Net Loss for the year was (57.53 M) with loss before taxes, overhead, and interest of (12.79 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Opus Genetics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Opus Genetics and how it compares across the competition.
About Opus Genetics Valuation
The stock valuation mechanism determines Opus Genetics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Opus Genetics. We calculate exposure to Opus Genetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Opus Genetics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 12.6 M | 15.5 M | |
| Pretax Profit Margin | (4.71) | (4.95) | |
| Operating Profit Margin | (5.08) | (5.34) | |
| Net Loss | (4.71) | (4.95) | |
| Gross Profit Margin | 0.90 | 0.80 |
Opus Genetics Current Valuation Indicators
Valuation refers to the process of determining the present value of Opus Genetics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Opus we look at many different elements of the entity such as Opus's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Opus Genetics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Opus Genetics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Opus Genetics' worth.Complementary Tools for Opus Stock analysis
When running Opus Genetics' price analysis, check to measure Opus Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics is operating at the current time. Most of Opus Genetics' value examination focuses on studying past and present price action to predict the probability of Opus Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics' price. Additionally, you may evaluate how the addition of Opus Genetics to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world |